CRISPR Overhauls CAR-T Pipeline With Next-Gen Candidates, Autoimmune Expansion

 
• By Alaric DeArment

Experts see allogeneic CAR-Ts as less likely to carry potential risks of T-cell malignancies, and an opportunity for differentiation against the crowded autologous CD19-directed CAR-T space.

CRISPR said it would shift the focus in its CAR-T pipeline to next-gen candidates. • Source: Shutterstock

More from Strategy

More from Business